|
Market Closed -
Euronext Paris
11:55:00 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 0.3440 EUR | -3.37% |
|
-9.71% | +15.44% |
| 09-11 | Chinese Regulator Accepts Nicox's Glaucoma Drug Application for Review | MT |
| 09-11 | Nicox S.A. Announces Acceptance Of NCX 470 NDA For Review In China | CI |
| Market Cap | 30.32M 35.19M 28.71M 26.02M 48.81M 3.36B 49.06M 341M 131M 1.71B 132M 129M 5.4B | P/E 2026 * |
-6.88x | P/E 2027 * | 17.2x |
|---|---|---|---|---|---|
| Enterprise Value | 30.32M 35.19M 28.71M 26.02M 48.81M 3.36B 49.06M 341M 131M 1.71B 132M 129M 5.4B | EV / Sales 2026 * |
10.1x | EV / Sales 2027 * | 3.03x |
| Free-Float |
99.65% | Yield 2026 * |
-
| Yield 2027 * | - |
Euronext ParisEUR
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ALCOX | Real-time | |
Börse Stuttgart
| NXOA | Delayed | |
|
Deutsche Boerse AG
| NXOA | Delayed | |
|
CBOE
| 0RCQ | Real-time | |
|
CBOE
| COXp | Real-time | |
|
Boerse Muenchen
| NXOA | Real-time |
| 1 day | -3.37% | ||
| 1 week | -9.71% | ||
| Current month | -11.57% | ||
| 1 month | -10.65% | ||
| 3 months | -0.58% | ||
| 6 months | -21.55% | ||
| Current year | +15.44% |
| 1 week | 0.34 |  | 0.38 |
| 1 month | 0.34 | | 0.4 |
| Current year | 0.29 | | 0.57 |
| 1 year | 0.28 | | 0.57 |
| 3 years | 0.14 | | 0.65 |
| 5 years | 0.14 | | 3.72 |
| 10 years | 0.14 | | 13.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
CEO | Chief Executive Officer | 55 | 2024-02-27 |
Sandrine Gestin
DFI | Director of Finance/CFO | 58 | 2014-12-31 |
Emmet Purtill
PRN | Corporate Officer/Principal | - | 2005-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
BRD | Director/Board Member | 55 | 2024-04-07 |
Damian Marron
CHM | Chairman | 64 | 2024-07-15 |
Marc Bozec
BRD | Director/Board Member | - | 2024-07-15 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 1/29/22 | Free | Chief Executive Officer | 15,000 | 0.0348% | ||
| 2/16/21 | Exercice | Chief Executive Officer | 10,000 | 0.0270% | ||
| 2/1/20 | Free | Chief Executive Officer | 10,000 | 0.0300% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.37% | -9.71% | -7.77% | -21.46% | 35.19M | |
| -0.54% | -4.26% | +69.03% | +32.53% | 355B | |
| -0.15% | -3.24% | +21.83% | -20.33% | 66.33B | |
| +0.19% | -2.71% | +38.27% | +185.87% | 12.17B | |
| -0.66% | -8.82% | -11.70% | -16.24% | 7.47B | |
| -4.80% | -8.31% | -28.14% | -8.74% | 4.64B | |
| +0.63% | -2.46% | -33.22% | +4.34% | 4.42B | |
| -1.24% | -6.98% | -34.91% | -13.14% | 2.86B | |
| -0.12% | -4.34% | -10.76% | +39.83% | 2.42B | |
| -1.84% | -5.00% | -28.35% | -23.61% | 1.9B | |
| Average | -1.19% | -5.12% | -2.57% | +15.91% | 45.73B | |
| Weighted average by Cap. | -0.51% | -4.15% | +56.59% | +26.97% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3M 3.48M 2.84M 2.57M 4.83M 333M 4.85M 33.74M 12.97M 169M 13.08M 12.79M 535M | 10M 11.61M 9.47M 8.58M 16.1M 1.11B 16.18M 112M 43.25M 564M 43.59M 42.63M 1.78B |
| Net income | -5M -5.8M -4.73M -4.29M -8.05M -554M -8.09M -56.23M -21.62M -282M -21.79M -21.32M -891M | 2M 2.32M 1.89M 1.72M 3.22M 222M 3.24M 22.49M 8.65M 113M 8.72M 8.53M 357M |
| Net Debt | - | - |
Employees
10
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-11 | €0.3440 | -3.37% | 492,385 |
| 26-09-10 | €0.3560 | -3.52% | 170,301 |
| 26-09-09 | €0.3690 | -1.86% | 214,565 |
| 26-09-08 | €0.3760 | +0.27% | 83,632 |
| 26-09-07 | €0.3750 | -1.57% | 294,126 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3440EUR
Average target price
1.000EUR
Spread / Average Target
+190.70%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALCOX Stock
Select your edition
All financial news and data tailored to specific country editions
